The prognostic significance of p63 cytoplasmic expression in colorectal cancer

References

1. ↵
   1. Ferlay J,
   2. Soerjomataram I,
   3. Ervik M,
   4. Dikshit R,
   5. Eser S,
   6. Mathers C,
   7. et al.

   (2012) GLOBOCAN. Cancer incidence and mortality worldwide (International Agency for Research on Cancer, Lyon (FR)).

   Google Scholar
2. ↵
   1. Bray F,
   2. Ren JS,
   3. Masuyer E,
   4. Ferlay J

   (2013) Estimates of global cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 132:1133–1145.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
3. ↵
   1. Ibrahim EM,
   2. Zeeneldin AA,
   3. El-Khodary TR,
   4. Al-Gahmi AM,
   5. Bin Sadiq BM

   (2008) Past, present and future of colorectal cancer in the Kingdom of Saudi Arabia. Saudi J Gastroenterol 14:178–182.

   OpenUrlGoogle Scholar
4. ↵
   Saudi Health Council. Annual Cancer Incidence Report for Saudi Cancer Registry (SCR), Available from https://nhic.gov.sa/eServices/Documents/2014.pdf. (Updated 2014; Accessed 2018 November 11).

   Google Scholar
5. ↵
   1. Albasri A,
   2. Yosef H,
   3. Hussainy AS,
   4. Sultan SA,
   5. Alhujaily A

   (2014) Histopathological features of colorectal cancer in Al-Madinah region of Saudi Arabia:8 years experience. Asian Pac J Cancer Prev 15:3133–3137.

   OpenUrlGoogle Scholar
6. ↵
   1. Soussi T,
   2. Wiman KG

   (2015) TP53:an oncogene in disguise. Cell Death Differ 22:1239.

   OpenUrlCrossRefPubMedGoogle Scholar
7. ↵
   1. Yougong C,
   2. Shijie P,
   3. Yimin F,
   4. Zhi-Xiong L,
   5. Chenghua X

   (2018) double dealing tale of p63:an oncogene or a tumor suppressor. Cell Mol Life Sci 75:965–973.

   OpenUrlCrossRefPubMedGoogle Scholar
8. ↵
   1. Massion PP,
   2. Taflan PM,
   3. Jamshedur Rahman SM,
   4. Yildiz P,
   5. Shyr Y,
   6. Edgerton ME,
   7. et al.

   (2003) Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 63:7113–7121.

   OpenUrlAbstract/FREE Full TextGoogle Scholar
9. ↵
   1. Reis-Filho JS,
   2. Simpson PT,
   3. Martins A,
   4. Preto A,
   5. Gärtner F,
   6. Schmitt FC

   (2003) Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 443:122–132.

   OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
10. ↵
    1. Bergholz J,
    2. Xiao ZX

    (2012) Role of p63 in development, tumorigenesis and cancer progression. Cancer Microenviron 5:311–322.

    OpenUrlCrossRefPubMedGoogle Scholar
11. ↵
    1. Carneiro FP,
    2. Ramalho LN,
    3. Britto-Garcia S,
    4. Ribeiro-Silva A,
    5. Zucoloto S

    (2006) Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Dis Colon Rectum 49:588–594.

    OpenUrlPubMedGoogle Scholar
12. ↵
    1. Guo HQ,
    2. Huang GL,
    3. Liu OF,
    4. Liu YY,
    5. Yao ZH,
    6. Yao SN,
    7. et al.

    (2012) p63 Expression is a prognostic factor in colorectal cancer. Int J Biol Markers 27:212–218.

    OpenUrlGoogle Scholar
13. ↵
    1. Bahnassy AA,
    2. Zekri AR,
    3. Salem SE,
    4. Abou-Bakr AA,
    5. Sakr MA,
    6. Abdel-Samiaa AG,
    7. et al.

    (2014) Differential expression of p53 family proteins in colorectal adenomas and carcinomas:Prognostic and predictive values. Histol Histopathol 29:207–216.

    OpenUrlPubMedGoogle Scholar
14. ↵
    1. Elkablawy MA,
    2. Albasri AM

    (2015) High quality tissue miniarray technique using a conventional TV/radio telescopic antenna. Asian Pac J Cancer Prev 16:1129–1133.

    OpenUrlCrossRefPubMedGoogle Scholar
15. ↵
    1. Albasri AM,
    2. Elkablawy MA,
    3. Hussainy AS,
    4. Yousif HM,
    5. Alhujaily AS

    (2018) Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients:An experience from Western Saudi Arabia. SaudiMed J 39:773–780.

    OpenUrlGoogle Scholar
16. ↵
    1. Ye S,
    2. Lee KB,
    3. Park MH,
    4. Lee JS,
    5. Kim SM

    (2014) p63 regulates growth of esophageal squamous carcinoma cells via the Akt signaling pathway. Int J Oncol 44:2153–2159.

    OpenUrlGoogle Scholar
17. ↵
    1. Fabbro M,
    2. Henderson BR

    (2003) Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp Cell Res 282:59–69.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
18. ↵
    1. Hood JK,
    2. Silver PA

    (2000) Diverse nuclear transport pathways regulate cell proliferation and oncogenesis. Biochim Biophys Acta 1471:M31–M41.

    OpenUrlPubMedGoogle Scholar
19. ↵
    1. Prall F,
    2. Hühns M

    (2019) Quantitative evaluation of TP53 immunohistochemistry to predict gene mutations:lessons learnt from a series of colorectal carcinomas. Hum Pathol 84:246–253.

    OpenUrlGoogle Scholar
20. 1. Inoue T,
    2. Stuart J,
    3. Leno R,
    4. Maki CG

    (2002) Nuclear import and export signals in control of the p53-related protein p73. J Biol Chem 277:15053–15060.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
21. ↵
    1. Narahashi T,
    2. Niki T,
    3. Wang T,
    4. Goto A,
    5. Matsubara D,
    6. Funata N,
    7. et al.

    (2006) Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. Histopathology 49:349–57.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
22. ↵
    1. Dhillon PK,
    2. Barry M,
    3. Stampfer MJ,
    4. Perner S,
    5. Fiorentino M,
    6. Fornari A,
    7. et al.

    (2009) Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 18:595–600.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
23. ↵
    1. Stindt MH,
    2. Muller PA,
    3. Ludwig RL,
    4. Kehrloesser S,
    5. Dötsch V,
    6. Vousden KH

    (2015) Functional interplay between MDM2, p63/p73 and mutant p53. Oncogene 34:4300–4310.

    OpenUrlCrossRefPubMedGoogle Scholar
24. ↵
    1. Lo Muzio L,
    2. Santarelli A,
    3. Caltabiano R,
    4. Rubini C,
    5. Pieramici T,
    6. Trevisiol L,
    7. et al.

    (2005) p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol 36:187–194.

    OpenUrlCrossRefPubMedGoogle Scholar
25. 1. Koga F,
    2. Kawakami S,
    3. Kumagai J,
    4. Takizawa T,
    5. Ando N,
    6. Arai G,
    7. et al.

    (2003) Impaired Delta Np63 expression associates with reduced beta-catenin and aggressive phenotypes of urothelial neoplasms. Br J Cancer 88:740–747.

    OpenUrlCrossRefPubMedGoogle Scholar
26. ↵
    1. Sethi I,
    2. Romano RA,
    3. Gluck C,
    4. Smalley K,
    5. Vojtesek B,
    6. Buck MJ,
    7. Sinha S

    (2015) A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues. BMC Genomics 16:584.

    OpenUrlCrossRefGoogle Scholar
27. ↵
    1. Agilent Dako

    Monoclonal Mouse Anti-Human p63 Protein. Clone 4A4 (product information), Available from http://www.dako.com/download.pdf?objectid=112041003. [Accessed 2018 November 13].

    Google Scholar
28. ↵
    1. Glickman JN,
    2. Yang A,
    3. Shahsafaei A,
    4. McKeon F,
    5. Odze RD

    (2001) Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Hum Pathol 11:1157–1165.

    OpenUrlGoogle Scholar
29. ↵
    1. Ferronika P,
    2. Triningsih FX,
    3. Ghozali A,
    4. Moeljono A,
    5. Rahmayanti S,
    6. Shadrina AN,
    7. et al.

    (2012) p63 cytoplasmic aberrance is associated with high prostate cancer stem cell expression. Asian Pac J Cancer Prev 13:1943–1948.

    OpenUrlPubMedGoogle Scholar
30. ↵
    1. Ribeiro-Silva A,
    2. ZambelliRamalho LN,
    3. Britto Garcia S,
    4. Zucoloto S

    (2003) The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch Pathol Lab Med 3:336–340.

    OpenUrlGoogle Scholar
31. 1. Wang BY,
    2. Gil J,
    3. Kaufman D,
    4. Gan L,
    5. Kohtz DS,
    6. Burstein DE

    (2002) P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol 33:921–926.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
32. ↵
    1. Xia W,
    2. Chen JS,
    3. Zhou X,
    4. Sun PR,
    5. Lee DF,
    6. Liao Y,
    7. Zhou BP,
    8. Hung MC

    (2004) Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 10:3815–3824.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
33. ↵
    1. Re M,
    2. Zizzi A,
    3. Ferrante L,
    4. Stramazzotti D,
    5. Goteri G,
    6. Gioacchini FM,
    7. Olivieri F,
    8. Magliulo G,
    9. Rubini C

    (2014) p63 and Ki-67 immunostainings in laryngeal squamous cell carcinoma are related to survival. European Archives of Oto-Rhino-Laryngology 271:1641–1651.

    OpenUrlCrossRefPubMedGoogle Scholar
34. ↵
    1. Melling N,
    2. Kowitz CM,
    3. Simon R,
    4. Bokemeyer C,
    5. Terracciano L,
    6. Sauter G,
    7. Izbicki JR,
    8. Marx AH

    (2016) High Ki67 expression is an independent good prognostic marker in colorectal cancer. Journal of Clinical Pathology 69:209–214.

    OpenUrlAbstract/FREE Full TextGoogle Scholar
35. ↵
    1. Andreyev HJ,
    2. Norman AR,
    3. Cunningham D,
    4. Oates J,
    5. Dix BR,
    6. Iacopetta BJ,
    7. Young J,
    8. Walsh T,
    9. Ward R,
    10. Hawkins N,
    11. et al.

    (2001) Kirsten ras mutations in patients with colorectal cancer:the 'RASCAL II'study. Br J Cancer 85:692–696.

    OpenUrlCrossRefPubMedWeb of ScienceGoogle Scholar
36. ↵
    1. Shen B,
    2. Li M,
    3. Wang H,
    4. Xin L,
    5. Xie J

    (2018) Expression and clinical significance of the RAS/RAF/MAPK cell signaling pathway in gastric cancer. Int J Clin Exp Med 11:11682–11689.

    OpenUrlGoogle Scholar
37. ↵
    1. Lan YT,
    2. Jen Kou L,
    3. Lin CH,
    4. Yang SH,
    5. Lin CC,
    6. Wang HS,
    7. Chen WS,
    8. Lin TC,
    9. Jiang JK,
    10. Chang SC

    (2015) Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers. J Surg Oncol 111:905–910.

    OpenUrlCrossRefPubMedGoogle Scholar